How to Take Benfotiamine: Dosage, Timing, and Safety

Most clinical trials of benfotiamine have used between 150 and 600 mg per day, typically split into two doses taken with meals. Because benfotiamine delivers thiamine (vitamin B1) to the bloodstream far more efficiently than standard thiamine supplements, the dosing logic is different from what you might expect if you are used to ordinary B-vitamin pills. Getting the dose, timing, and expectations right depends on why you are taking it and what the research actually supports.

Why Benfotiamine Instead of Regular Thiamine

Benfotiamine is a synthetic derivative of thiamine that was developed to solve a basic problem: standard thiamine (whether as thiamine hydrochloride or thiamine mononitrate) absorbs poorly from the gut, especially at higher doses. A pharmacokinetic study comparing the two found that benfotiamine delivered roughly 11 times more thiamine into the bloodstream than an equivalent oral dose of thiamine hydrochloride, and about twice as much of the active coenzyme form (thiamine diphosphate) inside red blood cells.¹ That gap matters because many of benfotiamine’s proposed benefits require sustained, high intracellular levels of thiamine diphosphate that plain thiamine struggles to achieve through oral dosing.

The way benfotiamine enters your cells is different from truly fat-soluble thiamine derivatives. It first has to be stripped of its phosphate group by enzymes (alkaline phosphatases) on the intestinal surface. The resulting molecule, S-benzoylthiamine, is fat-soluble enough to cross cell membranes and then gets converted into thiamine inside red blood cells and the liver.² This two-step process means benfotiamine is not instant: laboratory work shows it takes more than two hours of exposure before intracellular thiamine levels rise meaningfully.³ Understanding this lag helps explain why consistent, repeated dosing matters more than trying to load up in a single sitting.

Dosage Ranges Used in Clinical Research

There is no single “correct” dose of benfotiamine because it has been studied at different levels depending on the condition. Here is what the major clinical trials have actually used:

• 150 mg per day: The lowest dose commonly studied. An open trial in diabetic neuropathy patients used 150 mg daily as its low-dose arm and still found meaningful symptom improvement, though higher doses performed better.⁴
• 300 mg per day: A 24-month double-blind trial in people with type 1 diabetes used 300 mg daily to evaluate effects on nerve function and inflammatory markers.⁵
• 320 mg per day: The high-dose arm in the painful neuropathy trial mentioned above, which found the strongest benefit at this level.⁴
• 600 mg per day (300 mg twice daily): Used in a 12-month randomized controlled trial of type 2 diabetes patients with symptomatic polyneuropathy,⁶ and also in a phase IIa Alzheimer’s disease trial.⁷

A reference sometimes cited by clinicians puts the usual range at 150 to 300 mg, taken once or twice daily.⁸ If you are starting without specific medical guidance, 150 mg once or twice a day is where most people begin. Higher doses in the 300-to-600 mg daily range have been used in supervised research settings but are worth discussing with a healthcare provider, especially if you are managing a specific condition.

When and How Often to Take It

Splitting the daily dose into two servings, morning and evening, is the approach most clinical trials have used. The Alzheimer’s trial, for instance, explicitly gave participants one 300 mg capsule in the morning and one in the evening.⁷ The same twice-daily pattern was used in the 12-month polyneuropathy trial.⁶

The pharmacokinetics support this approach. After a single dose, free thiamine in the blood peaks within one to two hours, but the active coenzyme forms that actually do the work inside cells take much longer to build up: thiamine monophosphate peaks between about three and a half to eight hours, and thiamine diphosphate peaks somewhere between 8 and 24 hours.⁹ A formal dose-escalation study in healthy volunteers found that at 150 and 300 mg doses, thiamine had a half-life of roughly 10 to 14 hours. Over a week of repeated dosing, thiamine accumulated in the blood to about double the single-dose level.¹⁰ Thiamine diphosphate showed a similar accumulation pattern.

What this means practically: twice-daily dosing keeps your levels more stable, and you should expect it to take at least several days of consistent use before intracellular thiamine diphosphate reaches its full steady-state concentration. Do not judge whether benfotiamine “works” based on the first day or two.

Should You Take It with Food

Because benfotiamine must be dephosphorylated by intestinal enzymes before it can be absorbed, and because the resulting S-benzoylthiamine is fat-soluble, taking it alongside a meal that contains some fat is a reasonable strategy. The enzymatic step happens at the intestinal surface, and food slows transit through the gut, giving those enzymes more contact time with the benfotiamine molecule. Most clinical trials administered the supplement with meals, and the formal pharmacokinetic studies did not test fasting conditions as the primary protocol. While there is no direct head-to-head trial comparing absorption with food versus on an empty stomach, the biochemistry favors taking it with a meal. If you are splitting your dose, pairing each dose with breakfast and dinner is the simplest approach.

Safety Profile and Tolerability

Benfotiamine has a reassuring safety profile across the studies that have been published. The dose-escalation study in healthy volunteers tested single doses up to 1,200 mg and multiple daily doses at several levels over seven days, and reported no serious adverse events.¹⁰ The 24-month type 1 diabetes trial at 300 mg daily did not report significant treatment-related problems.⁵ An eight-week randomized trial in alcoholic polyneuropathy specifically noted no therapy-specific adverse effects.¹¹

Because benfotiamine is a water-soluble vitamin derivative (despite being better absorbed than standard thiamine), excess thiamine is excreted through the kidneys rather than stored in fat tissue. This means the risk of accumulating to toxic levels is inherently lower than with fat-soluble vitamins. That said, the longest controlled trial ran 24 months, and doses above 600 mg per day have limited long-term data. Occasional anecdotal reports mention mild gastrointestinal discomfort, skin reactions, or headache, but these have not appeared at meaningful rates in controlled trials.

One caution worth mentioning: if you are taking medications that interact with thiamine metabolism or if you have significant kidney impairment affecting your ability to excrete water-soluble compounds, talk to your doctor before starting. Benfotiamine is sold as a dietary supplement in most countries, not a prescription drug, which means it has not gone through the regulatory approval process that prescription medications require. Quality and dosing accuracy can vary between manufacturers.

What Benfotiamine Actually Does Inside the Body

The reason benfotiamine gets attention in diabetes research is its effect on a specific enzyme called transketolase. In high-sugar conditions, certain byproducts of glucose metabolism accumulate and cause damage through several pathways. Benfotiamine boosts transketolase activity by raising intracellular thiamine diphosphate (the coenzyme that transketolase needs). This redirects those harmful glucose byproducts into a safer metabolic route called the pentose phosphate pathway, reducing the formation of advanced glycation end products (AGEs) and quieting other damage pathways.^{12 13}

This is why benfotiamine is studied primarily in the context of diabetic complications: the damage it targets is driven specifically by chronic high blood sugar. People with normal glucose metabolism still need thiamine for energy production and other basic functions, but they are less likely to see dramatic benefits from megadoses.

Uses Beyond Diabetic Neuropathy

While diabetic neuropathy is the best-studied indication, benfotiamine has been tested in several other contexts. The evidence varies considerably depending on the condition.

In alcoholic polyneuropathy, an eight-week randomized controlled study found that benfotiamine significantly improved vibration perception, motor function, and overall symptom scores. Coordination and pain also showed a trend toward improvement.¹¹ Chronic alcohol use is one of the most common causes of thiamine deficiency worldwide, so this application makes straightforward biological sense.

For cognitive decline, a phase IIa trial tested 600 mg daily in people with mild-to-moderate Alzheimer’s disease. The rationale rests on observations that thiamine metabolism is disrupted in Alzheimer’s, and that boosting thiamine diphosphate might support brain glucose metabolism.⁷ This remains early-stage research, and the trial was designed to assess feasibility and biomarker changes rather than prove clinical efficacy.

In kidney disease related to diabetes, animal research showed that high-dose benfotiamine strongly inhibited the development of early-stage diabetic nephropathy (microalbuminuria) by activating the same transketolase pathway that protects nerves. It also reduced hyperfiltration, an early sign of kidney stress, and did this without lowering blood sugar levels.¹⁴ Translating animal kidney findings to human clinical outcomes is always uncertain, but the mechanism is consistent with what we know about how benfotiamine works.

Limitations of the Current Evidence

Anyone considering benfotiamine should understand that while the biochemical rationale is solid, the clinical trial evidence has real gaps. Most trials have been small, lasting weeks to months, and focused on symptom-based outcomes rather than hard endpoints like preventing amputations or blindness. A critical review of benfotiamine’s role in diabetic neuropathy concluded that no large-scale, long-term trials have been published.¹⁵ The BOND study, a 12-month randomized controlled trial published in 2025, is among the longest and most rigorous to date, but even it studied only about 80 participants per arm.⁶

The neuropathy trial from the early 1990s that found a dose-response relationship enrolled just 36 patients total across three arms.⁴ That is a thin foundation for confident dose recommendations, even if the direction of the findings is encouraging. This is a supplement where the lab science is ahead of the clinical proof, and it is worth keeping that gap in mind when setting your expectations.

Tracking Whether It Is Working

Benfotiamine’s effects are not something you will necessarily feel day to day, especially if you are taking it preventively rather than for active nerve pain. If you want an objective measure, your doctor can check your thiamine status through blood tests.

The most informative test measures thiamine diphosphate levels in red blood cells or whole blood. An alternative is the erythrocyte transketolase activity coefficient (ETKAC), which checks how saturated your transketolase enzyme is with its thiamine coenzyme. A value under 1.15 indicates good thiamine status, values between 1.15 and 1.25 suggest you are borderline, and anything above 1.25 signals a risk of deficiency.¹⁶ If you started benfotiamine because of documented or suspected thiamine deficiency, repeating this test after several weeks of consistent dosing can confirm whether your levels have actually improved.

For people using benfotiamine to manage neuropathy symptoms, the more practical tracking method is monitoring changes in pain, numbness, tingling, and balance over time. The clinical trials used standardized neurological scoring systems, but for personal use, keeping a simple symptom diary can serve the same purpose. Because the pharmacokinetics show that thiamine diphosphate accumulates over days of repeated dosing and nerve tissue responds slowly to metabolic changes, you should allow at least several weeks before evaluating whether your symptoms have shifted.

How Benfotiamine Fits with Other Supplements

People interested in benfotiamine for diabetic neuropathy often encounter alpha-lipoic acid, another supplement with its own evidence base for the same condition. The two work through different mechanisms: benfotiamine activates transketolase and diverts harmful glucose metabolites, while alpha-lipoic acid acts primarily as an antioxidant. Some practitioners recommend combining them, and the biochemical rationale for doing so is coherent, but there are no large randomized trials directly testing the combination against either agent alone.¹⁵

Some formulations bundle benfotiamine with other B vitamins, particularly B6 and B12. The early neuropathy trial used a benfotiamine-vitamin B combination product, with the high-dose arm delivering 320 mg of benfotiamine per day alongside B6 and B12.⁴ Whether the additional B vitamins contributed to the observed benefit or were simply along for the ride is unclear from that study’s design. If your diet already supplies adequate B6 and B12, a standalone benfotiamine product gives you cleaner control over dosing. If you suspect broader B-vitamin deficiency, the combination may cover more ground, but check your B12 status independently since benfotiamine does not address it.

Benfotiamine does not replace good blood sugar management. The animal kidney study found that benfotiamine reduced diabetic damage markers without changing blood glucose or glycated hemoglobin.¹⁴ That is encouraging from a mechanistic standpoint, but it also means benfotiamine is targeting downstream damage, not the root metabolic problem. Treating it as an add-on to, rather than a substitute for, glucose control and standard medical care is the approach most consistent with the evidence.